MDxHealth, Inc.To Present Results From Epigenetic Prostate Test To Identify Aggressive Prostate Cancer At The American Society of Clinical Oncology Genitourinary Cancers Symposium 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif. and HERSTAL, Belgium, Jan. 29, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, California, USA (January 30 - February 1, 2014).

Help employers find you! Check out all the jobs and post your resume.

Back to news